You probably never heard of Illumina (NASDAQ:ILMN) until Angelina Jolie penned an op-ed about her preventive bilateral mastectomy. Jolie had used Illumina's gene testing to determine her chance of getting breast and ovarian cancer. Her mother died of ovarian cancer at the age of 56, and Jolie was determined to take preventive measures on her own health.
Data on all tables from Best Stocks Now App
I, on the other hand, found Illumina using my Best Stocks Now app back in 2011, when I was writing my book of the same title. At that point in time, ILMN was priced around $71 and the company was a $9 billion mid-cap. Today, it is trading around $139, and the company is now a nearly $18 billion large-cap company.
Illumina, headquartered in San Diego, CA, applies innovative sequencing as well as array technologies to analyze genetic variation and function. What this means for you is that realization of personalized medicine is now closer than ever before.
Because of ILMN's innovation and dedication to its cause, going forward it will only cost $1,000 for a human genome sequence. Just one year ago, the cost was $10,000. A decade ago, $1 billion.
If ever there was a good story on capitalism and profit move, ILMN is it. It is also a Best Stock Now because this stock has the growth, performance, valuation, and stock chart that I like to see. I have a big position in ILMN and I have for quite some time.
- Over the last ten years, ILMN has quietly delivered 41% per year while the market has delivered a measly 5%.
- Over the last five years, ILMN has delivered 38% while the market has delivered 17%.
- Over the last three ILMN has returned 26% to investors while the market has delivered half of that at 13%.
- And over the last 12 months, ILMN is up 172%.
- ILMN gets an "A+" performance grade. It is one of the red-hot biotech stocks right now!
Illumina is not a cheap stock, but then again you do get what you pay for.
Valuation is my only concern with this stock, because the valuation grade I put on ILMN recently dropped down to a "C+". I still see over 80% upside potential in this stock over the next five years, however. So, ILMN does still meet my valuation requirement.
Lastly, we look at a chart of the stock.
ILMN's been blasting off for the past few weeks!
Out of 3,791 stocks in the Best Stocks Now app database, ILMN comes in at #5 currently. And it's been in my top 200 Best Stocks Now for the past year! This is why I have had a big position in the stock for my clients for quite some time.